Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: favourite (50), preference (97)

NIHR_RTB_PIS-ICF_v4.1_15Mar2023Localised

Description: 2 PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 4.1 15th March 2023 *If you require this information to be translated into another language or in a different format, please speak to a member of the Bio
Url: /Media/Southampton-Clinical-Research/Downloads/NIHR-RTB-PIS-ICF-v4.1-15Mar2023Localised.docx

Bevacizumab (15) Carboplatin-Paclitaxel (21 day)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (15)-CARBOPLATIN (AUC5)-PACLITAXEL (21 day) Regimen • Cervix-Bevacizumab (15)-Carboplatin (AUC5)-Paclitaxel (2
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/Bevacizumab-15-Carboplatin-Paclitaxel-21-day.pdf

Carboplatin(AUC5)-Paclitaxel_7day

Description: Chemotherapy Protocol BREAST CANCER CARBOPLATIN (AUC 5)-PACLITAXEL(7 day) Regimen • Breast-Carboplatin (AUC 5)-Paclitaxel (7 day) Indication • Neo-adjuvant treatment
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/CarboplatinAUC5-Paclitaxel-7day.pdf

Annual-report-2018-19

Description: ANNUAL REPORT AND ACCOUNTS 2018/19 incorporating the quality account 2018/19 Presented to Parliament pursuant to
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2018-19.pdf

InP-LEAM

Description: Chemotherapy Protocol LYMPHOMA LOMUSTINE-CYTARABINE-ETOPOSIDE (split)-MELPHALAN (LEAM) Inpatient Regimen Regimen Ly
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-LEAM.pdf

Cytarabine(SC)-Venetoclax

Description: Chemotherapy Protocol Acute Myeloid Leukaemia CYTARABINE (SC) - VENETOCLAX Regimen  AML – Cytarabine (SC) -Venetoclax Indication  Newly dia
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/CytarabineSC-Venetoclax.pdf

Annual report 20-21

Description: 2020/21 Incorporating the quality report University Hospital Southampton NHS Foundation Trust Annual Report and Accoun
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-20-21.pdf

RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab

Description: Chemotherapy Protocol LYMPHOMA CISPLATIN-DEXAMETHASONE-GEMCITABINE-RITUXIMAB (RGDP) Regimen • Lymphoma – RGDP-Cisplatin-Dexame
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab.pdf

REPOCH (dose adjusted)-Cyclophosphamide-Doxorubicin-Etoposide-Prednisolone-Rituximab-Vincristine

Description: Chemotherapy Protocol LYMPHOMA REPOCH - CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONERITUXIMAB-VINCRISTINE (Dose adjusted regimen) There are multiple versions of this p
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/REPOCH-dose-adjusted-Cyclophosphamide-Doxorubicin-Etoposide-Prednisolone-Rituximab-Vincristine.pdf

Lenalidomide-RituximabIV/SC

Description: Chemotherapy Protocol LYMPHOMA LENALIDOMIDE-RITUXIMAB (IV/SC) There are multiple versions of this protocol in u
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lenalidomide-RituximabIVSC.pdf

131 to 140 of 404

Previous … 12 13 14 15 16 … Next